News

2006 Press Releases

December 19, 2006
Advaxis Partners with Gynecologic Oncology Group for Phase II Study of Company’s Lead Cervical Cancer Vaccine

December 18, 2006
Advaxis Names Thomas A. Moore to Serve as CEO and Chairman of the Board

November 7, 2006
Advaxis Completes Dosing and Enrollment of First Cohort of Patients in Phase I/II Cervical Cancer Vaccine Trial

October 30, 2006
Advaxis to Present at Rodman & Renshaw 8th Annual Healthcare Conference on November 8, 2006

September 25, 2006
Advaxis Meets with FDA Regarding Phase II of Lovaxin C

September 11, 2006
Advaxis Appoints Thomas A. Moore to its Board of Directors
Todd Derbin Resigns as Chairman of the Board

June 15, 2006
Advaxis Begins Patient Education Initiative to Promote Better Understanding of Cervical Cancer Vaccines
Vice President of Clinical Development Interviewed by Television Stations Nationwide

May 15, 2006
Advaxis Continues Advancement of Two Listeria Vaccines Targeting Cancers Affecting Women

May 2, 2006
Advaxis Enrolls Patients to Cervical Cancer Vaccine Trial

March 7, 2006
Advaxis Inc. Announces Approvals of Israeli and Mexican Regulators to Commence Clinical Study of its Listeria Cancer Vaccine Candidate for Cervical Cancer

March 2, 2006
Advaxis, inc. to Present at the 5th Annual North American Forum for Investing and Partnering in Biotech and Medtech in Boston

February 28, 2006
Fredrick D. Cobb Appointed Vice President of Finance at Advaxis

February 21, 2006
Advaxis’s Listeria Cancer Vaccine Receives Regulatory Approval for Phase I/II testing in cervical cancer

February 13, 2006
Experienced Scientific Researcher Joins Advaxis to Advance Development
Of Cancer Vaccines

February 6, 2006
Advaxis Inc. Completes $3 Million Institutional Financing

Home